Most recently on footwear brand company Dr. Martens (DOCS), in July with the shares at 73.5p I questioned how much “on track” with strategic objectives towards “the world’s most-desired premium footwear brand”. The shares most recently closed at 63.4p and what about now “H1 FY27 Results” and the shares currently falling towards 52p?
Describing itself as “an iconic British footwear brand”, Dr. Martens (DOCS) has issued an “AGM Trading Update” emphasising “we are focused on our ambition to become the world’s most-desired premium footwear brand and are on track with our strategic objectives for FY”. However an “ambition” can be quite different to the reality, so how “on track” towards its ambition does the company currently look?
Describing itself as “an iconic British footwear brand”, Dr. Martens (DOCS) has issued a “Q3 FY26 Trading Statement” headlined “Good progress executing our consumer-first strategy and remain on track for significant profit growth in FY26”. So what about a currently more than 11% lower share price response to below 67p?
Most recently on self-described “iconic British footwear brand” Dr. Martens (DOCS), last month with the shares at around 95p I wrote ‘argues new “exciting partnerships”, but why’s it any financial details daring not to speak their name?’. The shares most recently closed at 81.6p and what about now “happy with the advances we're making”-stated results… and the shares currently at 73.15p?
Self-described “iconic British footwear brand” Dr. Martens (DOCS) has announced what it describes as “exciting partnerships… consistent with our strategy of entering new growth markets to reach more consumers than ever before through a capital-light approach”. How significant do the partnerships look from a current around £920 million market cap with the shares around 95p?
Footwear brand company Dr. Martens (DOCS) has announced results for its year ended 30th March 2025 headlined “Strong delivery against our FY25 objectives; guiding to a return to profit growth in FY26” and “Sharing today our strategic update, Levers For Growth, with the ambition of establishing Dr. Martens as the world's most-desired premium footwear brand”. How do those compare to the valuation at a currently rising above 70p share price?
Footwear brand company Dr. Martens (DOCS) has issued a trading statement with new CEO Ije Nwokorie emphasising “USA DTC in positive growth in Q3… great confidence for FY25 and beyond”. Er, so what about the shares, already down from near 100p as recently as last April, in response currently further down towards 70p?
Footwear brand company Dr. Martens (DOCS) has announced results for its half-year ended 29th September 2024 headlined “Results in line with expectations and delivering on our strategic objectives”. What of a current share price response up to around 65p?
Footwear brand company Dr. Martens (DOCS) has announced results for its year ended 31st March 2024 including “DTC revenue up 2% (5% Constant Currency)” and that “current trading is in line with our expectations”. What about these from a current up to 87.3p share price, though down from above 150p less than a year ago?
Previously on footwear brand company Dr. Martens (DOCS), in January I wrote Q3 ‘in line with full year guidance’, but that’s not really an achievement, concluding with the shares around 81p that the trading trajectory and financials suggested still an IPO Roll-Call of Shame avoid/sell. The shares most recently closed at 94.95p, but what of them currently down to below 70p following announcements from the company today?
